Skip to main content

Advertisement

SpringerLink
Log in

CDHR5 inhibits proliferation of hepatocellular carcinoma and predicts clinical prognosis

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

As one of the most prevalent malignancies, hepatocellular carcinoma (HCC) ranks the third leading cause of cancer death worldwide. Due to the lack of biomarkers for early diagnosis, the clinical outcome of HCC remains unsatisfied with the current common therapeutic approaches, including surgery and chemotherapies. Thus, sensitive biomarkers and targeted therapies are in great need.

Aims

In this study, we explored and verified whether CDHR5 (cadherin-related family member 5), a cadherin family protein, could serve as the potential biomarkers for HCC in the clinic.

Methods

A retrospective study which contained 154 HCC patients was performed. Chi-square was utilized to analyze the relationship between CDHR5 expression and the clinicopathological features of HCC patients. The Kaplan–Meier method and Cox regression analyses were then used to evaluate the survival of HCC patients. In addition, cell proliferation assay and colony formation assay were performed to examine the effects of CDHR5 on the progression of HepG2 and Huh7 cells.

Results

IHC and RT-qPCR revealed that CDHR5 was downregulated in HCC tissues compared with adjacent liver tissues. In addition, CDHR5 expression was significantly correlated with tumor numbers, tumor size, and TNM stage. CDHR5 expression was then shown to be an independent risk factor for survival of HCC patients by survival analysis. In vitro experiments showed that CDHR5 suppressed the proliferation capacity of HCC cells.

Conclusions

Taken together, our study not only identified CDHR5 as a novel prognostic biomarker in HCC but also provided evidence that CDHR5 can inhibit HCC cell proliferation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492

    Article  PubMed  Google Scholar 

  2. Zhang Y, Jia QA, Kadel D, Zhang XF, Zhang QB (2018) Targeting mTORC1/2 complexes inhibit tumorigenesis and enhance sensitivity to 5-flourouracil (5-FU) in hepatocellular carcinoma: a preclinical study of mTORC1/2-targeted therapy in hepatocellular carcinoma (HCC). Med Sci Monit 24:2735–2743. https://doi.org/10.12659/msm.907514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wang X, Zhang Q, Wang Y, Zhuang H, Chen B (2018) Clinical significance of ubiquitin specific protease 7 (USP7) in predicting prognosis of hepatocellular carcinoma and its functional mechanisms. Med Sci Monit 24:1742–1750

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022

    Article  PubMed  Google Scholar 

  5. Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251(5000):1451–1455

    Article  CAS  PubMed  Google Scholar 

  6. Liu H, Zhang Q, Li K, Gong Z, Liu Z, Xu Y, Swaney MH, Xiao K, Chen Y (2016) Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into β-arrestin-dependent ERK signaling. Oncotarget 7(49):81223

    PubMed  PubMed Central  Google Scholar 

  7. Hazan RB, Qiao R, Keren R, Badano I, Suyama K (2004) Cadherin switch in tumor progression. Ann N Y Acad Sci 1014(1):155–163

    Article  CAS  PubMed  Google Scholar 

  8. Wang C, Yu G, Liu J, Wang J, Zhang Y, Zhang X, Zhou Z, Huang Z (2012) Downregulation of PCDH9 predicts prognosis for patients with glioma. J Clin Neurosci 19(4):541–545

    Article  CAS  PubMed  Google Scholar 

  9. Li Z, Chim JC, Yang M, Ye J, Wong BC, Qiao L (2012) Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta Mol Cell Res 1823(2):298–305

    Article  CAS  Google Scholar 

  10. Zhong X, Zhu Y, Mao J, Zhang J, Zheng S (2013) Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancer. J Cancer Res Clin Oncol 139(3):485–490

    Article  CAS  PubMed  Google Scholar 

  11. Yu J, Koujak S, Nagase S, Li C, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M (2008) PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 27(34):4657–4665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Goldberg M, Peshkovsky C, Shifteh A, Al-Awqati Q (2000) μ-Protocadherin, a novel developmentally regulated protocadherin with mucin-like domains. J Biol Chem 275(32):24622–24629

    Article  CAS  PubMed  Google Scholar 

  13. Woo YM, Shin Y, Hwang JA, Hwang YH, Lee S, Park EY, Kong HK, Park HC, Lee YS, Park JH (2015) Epigenetic silencing of the MUPCDH gene as a possible prognostic biomarker for cyst growth in ADPKD. Sci Rep 5:15238. https://doi.org/10.1038/srep15238

    Article  CAS  PubMed  Google Scholar 

  14. Losi L, Grande A (2014) Involvement of mu-protocadherin in colorectal carcinogenesis: a promise for clinico-pathological evaluation. Histol Histopathol 29(1):11–19. https://doi.org/10.14670/hh-29.11

    Article  CAS  PubMed  Google Scholar 

  15. Montorsi L, Parenti S, Losi L, Ferrarini F, Gemelli C, Rossi A, Manco G, Ferrari S, Calabretta B, Tagliafico E, Zanocco-Marani T, Grande A (2016) Expression of mu-protocadherin is negatively regulated by the activation of the beta-catenin signaling pathway in normal and cancer colorectal enterocytes. Cell Death Dis 7:e2263. https://doi.org/10.1038/cddis.2016.163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Losi L, Parenti S, Ferrarini F, Rivasi F, Gavioli M, Natalini G, Ferrari S, Grande A (2011) Down-regulation of mu-protocadherin expression is a common event in colorectal carcinogenesis. Hum Pathol 42(7):960–971. https://doi.org/10.1016/j.humpath.2010.10.009

    Article  CAS  PubMed  Google Scholar 

  17. Hou S, Du P, Wang P, Wang C, Liu P, Liu H (2017) Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer. Clin Transl Oncol 19(9):1107–1116

    Article  CAS  PubMed  Google Scholar 

  18. Liu H, Xu Y, Zhang Q, Yang H, Shi W, Liu Z, Li K, Gong Z, Ning S, Li S (2017) Prognostic significance of TBL1XR1 in predicting liver metastasis for early stage colorectal cancer. Surg Oncol 26(1):13–20

    Article  PubMed  Google Scholar 

  19. Xu Y, Yang X, Li Z, Li S, Guo S, Ismail S, Liu H, Huang Z, Zhang Z, Chen Y (2017) Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression. Oncotarget 8(3):4888

    Article  PubMed  Google Scholar 

  20. Xu YF, Liu HD, Liu ZL, Pan C, Yang XQ, Ning SL, Zhang ZL, Guo S, Yu JM (2018) Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR 2 signalling. J Cell Mol Med 22(11):5596–5606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Liu H, Liu Z, Li K, Li S, Song L, Gong Z, Shi W, Yang H, Xu Y, Ning S (2017) TBL1XR1 predicts isolated tumor cells and micrometastasis in patients with TNM stage I/II colorectal cancer. J Gastroenterol Hepatol 32(9):1570–1580

    Article  CAS  PubMed  Google Scholar 

  22. Liu S, Chen L, Xu Y (2018) Significance of PYK2 level as a prognosis predictor in patients with colon adenocarcinoma after surgical resection. OncoTargets Ther 11:7625–7634. https://doi.org/10.2147/ott.s169531

    Article  CAS  Google Scholar 

  23. Zhang Q, Fan H, Zou Q, Liu H, Wan B, Zhu S, Hu Y, Li H, Zhang C, Zhou L (2018) TEAD 4 exerts pro-metastatic effects and is negatively regulated by miR6839-3p in lung adenocarcinoma progression. J Cell Mol Med 22(7):3560–3571

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Liu H, Xu Y, Zhang Q, Li K, Wang D, Li S, Ning S, Yang H, Shi W, Liu Z (2017) Correlations between TBL1XR1 and recurrence of colorectal cancer. Sci Rep 7:44275

    Article  PubMed  PubMed Central  Google Scholar 

  25. Bujko M, Kober P, Statkiewicz M, Mikula M, Ligaj M, Zwierzchowski L, Ostrowski J, Siedlecki JA (2015) Epigenetic-mediated downregulation of μ-protocadherin in colorectal tumours. Gastroenterol Res Pract 2015:317093

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Yidu Central Hospital of Weifang, Weifang, 262500, Shandong, China

    Xue Ding, Xiaomin Tian & Wei Liu

  2. Department of Immunology and Rheumatology, Gansu Provincial Hospital, Lanzhou, 730000, Gansu, China

    Zijia Li

Authors
  1. Xue Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaomin Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zijia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zijia Li.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ding, X., Tian, X., Liu, W. et al. CDHR5 inhibits proliferation of hepatocellular carcinoma and predicts clinical prognosis. Ir J Med Sci 189, 439–447 (2020). https://doi.org/10.1007/s11845-019-02092-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-019-02092-7

Keywords

Search

Navigation